Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

This is an interventional treatment trial for 2009 H1N1 Influenza focused on measuring Influenza, H1N1 Read More

Inclusion Criteria:

• Aged between 4 and 9 years, inclusive.
• Pre-vaccination serum HAI titer to A/California/07/09 of 8 or less
• No prior history of laboratory documented infection with novel H1N1 virus or immunization with novel H1N1 vaccine.
• in good health, as determined by: vital signs (heart rate <140 bpm; blood pressure: systolic ≥ 90 mm Hg and ≤140 mm Hg; diastolic ≤ 90 mm Hg; oral temperature <100.0ºF); medical history; and targeted physical examination, when necessary, based on medical history. Stable medical condition is defined as: no recent increase in prescription medication, dose, or frequency of medication in the last 3 months and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months.
• subject/parents are able to understand and comply with the planned study procedures, including being available for all study visits.
• subject/parents have provided informed consent prior to any study procedures. (An assent will be obtained for all children 6 years and older)

Exclusion Criteria:

• a previous history of vaccination against novel H1N1 virus or a laboratory documented history of previous novel H1N1 infection.
• History of egg allergy or allergy to other components of vaccine.
• History of wheezing.
• immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.
• has an active neoplastic disease.
• has long-term (greater than 2 weeks) use of oral or parenteral steroids, or high-dose inhaled steroids (>800 mg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).
• received immunoglobulin or another blood product within the 3 months prior to enrollment in this study.
• has received an inactivated vaccine within the 2 weeks or a live vaccine within the 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for vaccine naïve recipients).
• has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions include chronic conditions recognized as risk factors for influenza complications or as contraindications for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment.
• has an acute illness or an oral temperature greater than 99.9 degrees F (37.7 degrees C) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated symptoms resolved are eligible to enroll as long as treatment is completed and symptoms resolve > 3 days prior to enrollment.
• is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period.
• has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
• has a known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
• has a previous history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccination.
• has any condition that the principal investigator (PI) believes may interfere with successful completion of the study.